Palopegteriparatide clinical trials
Also written Yorvipath.
How each study uses Palopegteriparatide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Palopegteriparatide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 9 Aug 2024 · YORVIPATH · NDA 216490 (FDA, Drugs@FDA)
- European Union
- 17 Nov 2023 · Yorvipath · EMEA/H/C/005934 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Ascendis Pharma Bone Diseases A/S (2) · Ascendis Pharma A/S (2) · Visen Pharmaceuticals (Shanghai) Co., Ltd. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 2 in phase 3
Studies that test Palopegteriparatide, phase 3 first.
- Jun 2027A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With HypoparathyroidismPhase 3 · Ascendis Pharma Bone Diseases A/S
- Aug 2027A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term HypoparathyroidismPhase 3 · Ascendis Pharma A/S
Studies
Open first, then newest update. How each study uses Palopegteriparatide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With HypoparathyroidismRecruitingPhase 3Ascendis Pharma Bone Diseases A/SNCT07081997Written as Palopegteriparatide Experimental Arm
- A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term HypoparathyroidismRecruitingPhase 3Ascendis Pharma A/SNCT07706764Written as Palopegteriparatide
- A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With HypoparathyroidismCompletedPhase 3Ascendis Pharma Bone Diseases A/SNCT04701203Written as TransCon PTH
- A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With HypoparathyroidismCompletedPhase 2Ascendis Pharma A/SNCT04009291Written as TransCon PTH
- PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With HypoparathyroidismCompletedPhase 3Visen Pharmaceuticals (Shanghai) Co., Ltd.NCT05387070Written as TransCon PTH
Codes
What other systems call Palopegteriparatide · ClinicalTrials.gg INT002129
- MeSH (NLM) C000731747PalopegteriparatideOne source NLM
- UNII (FDA) G2N64C3385PALOPEGTERIPARATIDEConfirmed FDA, NLM
- NCI Thesaurus C179112PalopegteriparatideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731747 | Palopegteriparatide | One source NLM |
| UNII (FDA) | G2N64C3385 | PALOPEGTERIPARATIDE | Confirmed FDA, NLM |
| NCI Thesaurus | C179112 | Palopegteriparatide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.